The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2017 | What treatments are available for mesothelioma?
Johan Vansteenkiste, MD, PhD, from the University Hospitals Leuven, Leuven, Belgium, discusses the treatment of mesothelioma at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. Mesothelioma can be difficult to treat, and many patients relapse quickly. There are Phase III trials ongoing, for example, the French MAPS2 study (NCT02716272) investigated the use of nivolumab as monotherapy vs the combination of nivolumab plus ipilimumab in patients with relapsed mesothelioma. The results from this trial are encouraging, however more research still needs to be done.
